Artificial Intelligence in Drug Discovery Market to Reach $8.53 Billion by 2030

Strategic Insights -

The global artificial intelligence in drug discovery market has witnessed significant growth in recent years as pharmaceutical companies increasingly adopt AI to accelerate and optimize drug discovery processes. According to a report by ResearchAndMarkets.com, the market was valued at USD 1.72 billion in 2024 and is projected to reach USD 8.53 billion by 2030, rising at a compound annual growth rate (CAGR) of 30.59%. This rapid growth is driven by the increasing use of AI-powered technologies, including machine learning, deep learning, and natural language processing, which enable researchers to navigate the complexity of biological systems, analyze vast biomedical datasets, and identify promising drug candidates faster and at reduced costs.

Key Takeaways:

  • The global AI in drug discovery market exhibits significant regional diversity, with each geography offering unique opportunities and challenges.
  • North America leads the global AI in drug discovery market, accounting for a global share of over 43% in 2024, driven by its advanced technological ecosystem, robust pharmaceutical and biotechnology sectors, and substantial investments in research and development.
  • Leading pharmaceutical firms such as Pfizer, Novartis, Roche, and AstraZeneca have incorporated AI technologies into their research pipelines, collaborating with AI startups to drive innovation.
  • Startups and specialized AI companies, such as BenevolentAI, Insilico Medicine, Atomwise, Exscientia, and Recursion Pharmaceuticals, are at the forefront in the AI in drug discovery market, developing AI algorithms capable of analyzing complex biological data, predicting molecular interactions, and accelerating preclinical drug discovery stages.
  • The integration of AI with big data and omics technologies is reshaping the global drug discovery market, enabling a deeper understanding of biological systems, improving efficiency, and driving personalized medicine.
  • The increasing use of generative AI models is creating new opportunities across the healthcare ecosystem, enabling faster, cheaper, and more precise drug development.
  • The emergence of AI-driven drug repurposing is transforming traditional approaches, reducing costs, accelerating timelines, and addressing unmet medical needs.
  • Growing partnerships between pharmaceutical companies and AI-focused expertise are creating new opportunities for faster, more cost-effective, and innovative drug development.
  • Advancements in computing power and cloud technologies are empowering pharmaceutical companies and research institutions to revolutionize drug development processes, making them faster, more efficient, and more accessible.
  • Rising R&D costs in drug discovery are pushing the pharmaceutical industry to embrace innovative solutions, with AI emerging as a powerful enabler.
  • The growing volume of biological and clinical data is driving the global AI in drug discovery market, enabling the analysis of vast and complex datasets and unlocking new frontiers in drug discovery.

Statistics:

  • The global AI in drug discovery market was valued at USD 1.72 billion in 2024 and is projected to reach USD 8.53 billion by 2030, rising at a CAGR of 30.59%.
  • North America accounts for a global share of over 43% in 2024, driven by its advanced technological ecosystem, robust pharmaceutical and biotechnology sectors, and substantial investments in research and development.
  • The APAC region is witnessing exponential growth in the AI in drug discovery market, fueled by increasing healthcare investments, a growing pharmaceutical sector, and government support.
  • The Middle East, Africa, and Latin America represent nascent but promising markets driven by government support and increasing investments in healthcare innovation.

Sources:

  • "Artificial Intelligence (AI) in Drug Discovery Market - Global Outlook & Forecast 2025-2030" report by ResearchAndMarkets.com
  • Various sources cited within the report, including news articles and research papers.